CN110724192B - Hybridoma cell strain secreting serpentine monoclonal antibody and application thereof - Google Patents
Hybridoma cell strain secreting serpentine monoclonal antibody and application thereof Download PDFInfo
- Publication number
- CN110724192B CN110724192B CN201911272254.8A CN201911272254A CN110724192B CN 110724192 B CN110724192 B CN 110724192B CN 201911272254 A CN201911272254 A CN 201911272254A CN 110724192 B CN110724192 B CN 110724192B
- Authority
- CN
- China
- Prior art keywords
- serpentine
- monoclonal antibody
- hybridoma cell
- solution
- cell strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 title claims abstract description 95
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 31
- 230000003248 secreting effect Effects 0.000 title claims abstract description 19
- 239000000427 antigen Substances 0.000 claims abstract description 32
- 108091007433 antigens Proteins 0.000 claims abstract description 32
- 102000036639 antigens Human genes 0.000 claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims abstract description 23
- 238000001514 detection method Methods 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 238000004321 preservation Methods 0.000 claims abstract description 9
- 238000009629 microbiological culture Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000002965 ELISA Methods 0.000 claims description 12
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 4
- 108060003552 hemocyanin Proteins 0.000 claims description 4
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 claims description 4
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 239000008055 phosphate buffer solution Substances 0.000 claims description 3
- 229940014800 succinic anhydride Drugs 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 241001597062 Channa argus Species 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 12
- 238000012216 screening Methods 0.000 abstract description 10
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 238000003018 immunoassay Methods 0.000 abstract description 3
- 230000003053 immunization Effects 0.000 description 27
- 238000002649 immunization Methods 0.000 description 27
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000012980 RPMI-1640 medium Substances 0.000 description 10
- 206010003445 Ascites Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000011725 BALB/c mouse Methods 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 239000005662 Paraffin oil Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000003760 magnetic stirring Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 2
- 229930013292 trichothecene Natural products 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- MUUGCDGGIVCSDT-UHFFFAOYSA-N [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O MUUGCDGGIVCSDT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- -1 amino, carboxyl Chemical group 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000010611 checkerboard assay Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229930185603 trichostatin Natural products 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A hybridoma cell strain secreting a serpentine monoclonal antibody and application thereof belong to the field of food safety immunodetection. The hybridoma cell strain OVA15 secreting the serpentine monoclonal antibody has been preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No. 18515. The serpentine monoclonal antibody secreted by the strain is used for detecting serpentine residues in food. The serpentine monoclonal antibody obtained by the invention has better detection sensitivity and specificity to serpentine; the detection limit, namely the addition amount corresponding to the inhibition rate of 20-80% is 1.57-22.6 ng/mL, and the IC is50The value was 5.97 ng/mL; the crossing rate of the serpentine analog is less than 1 percent. The invention also provides a brand-new snakelike rhzomorph complete antigen and a synthesis thought thereof, and the snakelike rhzomorph monoclonal antibody cell strain obtained by adopting the complete antigen screening can be used for immunoassay detection.
Description
Technical Field
The invention relates to a hybridoma cell strain secreting a serpentine monoclonal antibody and application thereof, and belongs to the field of food safety immunodetection.
Background
Snakes (DAS) are highly toxic secondary metabolites produced by fusarium, belong to trichothecene type a toxins, are widely distributed in the nature, and seriously harm human and animal health. Serpentines are natural contaminants of agricultural feed and food worldwide, commonly found in cereals, especially wheat, corn, rice, and have been shown by clinical studies to be highly toxic to various animal species. The main manifestations are anorexia, vomiting, growth inhibition, neurotoxicity, immunotoxicity, genotoxicity and hepatotoxicity. The potential threat of anorexia caused by trichothecene type a toxins is of particular concern from a human and animal health perspective.
Highly sensitive and specific trichostatin assays are of critical importance for assessing the safety of food and animal feed, since they are a serious hazard to human and animal health.
The traditional detection methods of the serpentine are a gas chromatography-mass spectrometry method, a capillary electrophoresis method, a high performance liquid chromatography and a capillary electrophoresis-mass spectrometry method, however, the pretreatment methods are complex and time-consuming, and are not suitable for rapid detection of a large number of samples, and in order to maintain the benefits of consumers, a high-efficiency and rapid detection method for the serpentine is needed to be established.
An enzyme-linked immunosorbent assay (ELISA) is an extremely high-efficiency, sensitive and rapid detection method, has low requirement on the purity of a sample during detection, is simple and convenient to operate, and is suitable for on-site rapid detection of a large number of samples, however, the premise of using the ELISA to detect the serpentine is to obtain a monoclonal antibody with high specificity and high sensitivity to the serpentine, so that a method for preparing the monoclonal antibody with high specificity and high sensitivity to the serpentine is very critical.
The invention tries to prepare the serpentine monoclonal antibody through the hybridoma cell, but in the process of preparing the hybridoma cell strain capable of secreting the serpentine monoclonal antibody, further research is needed on how to prepare the serpentine hapten and the serpentine complete antigen and how to make a mouse generate strong immunity; whether the prepared hybridoma cell strain can secrete the serpentine monoclonal antibody or not needs further verification; the specificity and sensitivity of the secreted serpentine rhzomorph monoclonal antibody also need to be further verified.
Disclosure of Invention
The invention aims to overcome the defects and provides a hybridoma cell strain secreting a snakelike rhzomorph monoclonal antibody and application thereof, wherein the snakelike rhzomorph monoclonal antibody secreted by the hybridoma cell strain has better specificity and detection sensitivity (IC)50A value of 5.97 ng/mL) can be used for establishing an immunological detection method of the serpentine and detecting the serpentine residue in the food.
According to the technical scheme, the hybridoma cell strain OVA15 secreting the serpentine monoclonal antibody is deposited in China general microbiological culture Collection center (CGMCC) of China Committee for culture Collection of microorganisms, and is classified and named as a monoclonal cell strain by the microbiological research institute of China academy of sciences No. 3 of West Lu 1 Hospital, North Kyoho, the Beijing city, the date of deposition is 2019, 10 months and 14 days, and the number of deposition is CGMCC No. 18515.
The invention provides a preparation method of a hybridoma cell strain OVA15 secreting a serpentine monoclonal antibody, which comprises the following steps:
(1) preparing a snakelike bacterin hapten and a snakelike bacterin complete antigen, and preparing the obtained snakelike bacterin complete antigen into an antigen-containing Freund adjuvant and an antigen-containing incomplete Freund adjuvant;
(2) injecting the obtained Freund adjuvant containing the antigen into a BALB/c mouse body through back subcutaneous injection for multiple times of immunization, wherein the complete Freund adjuvant containing the antigen is adopted for the first immunization, and the incomplete Freund adjuvant containing the antigen is adopted for the boosting immunization;
(3) collecting blood from the mice on the 7 th day after the 3 rd immunization process, detecting the serum immune titer and the immune suppression capacity of the mice through indirect ELISA, and screening the mice with high content of the serpentine rhzomorph antibody in the serum to obtain immunized mice;
(4) performing last boosting immunization on the screened mice by using incomplete Freund's adjuvant, and performing sprint immunization by intraperitoneal injection, wherein the sprint immunization is performed by using a snakelike rhzomorph complete antigen without Freund's adjuvant;
(5) fusing splenocytes and myeloma cells of BALB/c mice 3 days after the completion of the impact immunization by a polyethylene glycol (PEG 4000) method, culturing the fused cells by an RPMI-1640 culture medium, detecting positive cell pores by using indirect ELISA, further determining the inhibition effect of the positive cell pores by using an indirect competitive ELISA method, carrying out 3 times of subcloning on the positive cell pores with the best inhibition by using a limiting dilution method, and finally screening to obtain a hybridoma cell strain OVA15 capable of secreting the serpentine monoclonal antibody.
The immune process in the steps (2) and (4) comprises 1 first immunity, 4 boosting immunizations and 1 sprint immunity; one month is left between the first immunization and the boosting immunization, 21 days is left between the boosting immunization, and 18-21 days is left between the boosting immunization and the impact immunization; the first immunization dose is 80 mug/mouse, the boosting immunization dose is 40 mug/mouse, and the sprint immunization dose is 20 mug/mouse.
The invention provides a hybridoma cell strain OVA15 secreting a serpentine monoclonal antibody, a preparation method of the hybridoma cell strain OVA15 secreting the serpentine monoclonal antibody and application of the hybridoma cell strain OVA15 secreting the serpentine monoclonal antibody in preparation of the serpentine monoclonal antibody.
The invention provides a snakelike rhzomorph hapten which has the following structural formula:
the invention provides a preparation method of a snakelike rhzomorph hapten. And extracting the residue with chloroform and water, combining organic phases, and continuously blowing the organic phases with nitrogen to obtain the derivative HS-DAS.
In one embodiment of the invention, 1mg of S.S.sub.S. is dissolved in 300. mu.L of pyridine, 7.2mg of succinic anhydride and 3.4mg of DMAP for catalysis are added, and the reaction is carried out under the condition of 50 ℃ and magnetic stirring in the dark for 5 hours. The reaction was then quenched by the addition of 50. mu.L of water and blown dry with nitrogen. The residue was purified with 1mL of chloroform and 1mL of water 1: 1, extracting for three times, combining organic phases, and continuously blowing the organic phases by using nitrogen to obtain the derivative HS-DAS.
The invention provides application of the serpentine hapten in preparation of serpentine complete antigen, hybridoma cell strains secreting serpentine monoclonal antibodies and serpentine monoclonal antibodies.
The invention provides a serpentine complete antigen, which has the following structural formula:
the invention provides a preparation method of the serpentine complete antigen, which is characterized by dissolving a serpentine hapten into an N, N-dimethylformamide solution, adding N-hydroxysuccinimide (NHS) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC), and carrying out magnetic stirring reaction at room temperature (called liquid A). Adding hemocyanin (KLH) into phosphate buffer solution to obtain solution B (named as solution B), dropwise adding the solution A into the solution B, reacting at room temperature overnight, dialyzing by PBS solution, and removing unreacted small molecule hapten to obtain complete antigen.
In one embodiment of the invention, the method is to dissolve the serpentine hapten in N, N-dimethylformamide solution, add 3 times the mass of serpentine and N-hydroxysuccinimide (NHS) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC), and magnetically stir the reaction at room temperature for 6-8h (called solution A). Adding 2000 times mass of hemocyanin (KLH) into phosphate buffer to obtain solution B (named as solution B), dropwise adding the solution A into the solution B, reacting at room temperature overnight, dialyzing by PBS solution, and removing unreacted small molecule hapten to obtain the serpentine complete antigen.
In one embodiment of the invention, the Phosphate Buffered Saline (PBS) is present at a concentration of 0.01mol/L, pH of 7.4.
The invention provides application of the serpentine complete antigen or the preparation method of the serpentine complete antigen in preparation of hybridoma cell strains secreting serpentine monoclonal antibodies and serpentine monoclonal antibodies.
In one embodiment of the invention, the serpentine monoclonal antibody is secreted and produced by hybridoma cell strain OVA15 with the preservation number of CGMCC No. 18515.
The invention provides a preparation method of the serpentine monoclonal antibody, which comprises the steps of taking a BALB/c mouse, injecting paraffin oil into the abdominal cavity, injecting a hybridoma cell strain OVA15 with the preservation number of CGMCC No.18515 into the abdominal cavity, collecting ascites after injection, purifying the ascites, and storing the obtained monoclonal antibody at low temperature.
In one embodiment of the invention, the method is to take BALB/c mice 8-10 weeks old, inject 1mL paraffin oil into the abdominal cavity of each mouse, and inject 1X 10 paraffin oil into the abdominal cavity of each mouse 7 days later6Collecting ascites from 7 days, purifying the ascites by an octanoic acid-ammonium sulfate method, and storing the obtained monoclonal antibody at-20 ℃.
The invention provides an application of the serpentine monoclonal antibody or the preparation method of the serpentine monoclonal antibody in recognition of serpentine.
The invention provides a detection kit prepared by applying the hybridoma cell strain secreting the snakelike rhzomorph monoclonal antibody or the snakelike rhzomorph complete antigen or the snakelike rhzomorph monoclonal antibody, and the detection kit is used for detecting snakelike rhzomorph residues in food.
The food is specifically cereal.
The detection method is to prepare a reagent for detecting the serpentin by an ELISA competition method.
The invention has the beneficial effects that: the serpentine monoclonal antibody obtained by the invention has better detection sensitivity and specificity to serpentine; the detection limit, namely the addition amount corresponding to the inhibition rate of 20-80 percent, is 1.57-22.6 ng/mL, and the IC is50The value was 5.97 ng/mL; crossing rate of serpentine analog is less than 1%, and crossing rate = (IC of serpentine)50IC of/analogue50）×100%）。
The invention also provides a brand-new snakelike rhzomorph complete antigen and a synthesis thought thereof, and the snakelike rhzomorph monoclonal antibody cell strain obtained by adopting the complete antigen screening can be used for immunoassay detection.
Biological material sample preservation: a hybridoma cell strain OVA15 secreting serpentine monoclonal antibody has been deposited in China general microbiological culture Collection center (CGMCC), China academy of sciences microorganism institute No. 3, West Lu No.1 institute of North Chen West Lu, Kyoho, Beijing, and is classified and named as monoclonal cell strain, the preservation date is 2019, 10 and 14 days, and the preservation number is CGMCC No. 18515.
Drawings
FIG. 1 is a standard curve of inhibition of a serpentine monoclonal antibody against serpentine.
Detailed Description
The following examples are provided as further illustration of the invention and are not to be construed as limitations or limitations of the invention.
The media involved in the following examples are as follows: PMI-1640 medium.
The reagents involved in the following examples are as follows:
carbonate Buffer (CBS): weighing Na2CO3 1.59 g，NaHCO32.93 g, respectively dissolved inMixing a small amount of double distilled water, adding the double distilled water to about 800mL, uniformly mixing, adjusting the pH value to 9.6, adding the double distilled water to a constant volume of 1000mL, and storing at 4 ℃ for later use;
phosphate Buffered Saline (PBS): 8.00g NaCl, 0.2g KCl, 0.2g KH2PO4，2.9g Na2HPO4·12 H2Dissolving O in 800mL of pure water, adjusting the pH value to 7.2-7.4 by using NaOH or HCl, and fixing the volume to 1000 mL;
PBST: PBS containing 0.05% tween 20;
TMB color development liquid: solution A: na (Na)2HPO4·12H218.43g of O, 9.33g of citric acid and pure water to reach the constant volume of 1000 mL; and B, liquid B: 60mg of TMB was dissolved in 100mL of ethylene glycol. A. And the volume ratio of the solution B to the solution B is 5: 1 to obtain the TMB color developing solution which is mixed at present.
The detection methods referred to in the following examples are as follows:
the serpentine inhibition rate detection method comprises the following steps: the most suitable antigen and antibody concentrations in the ic-ELISA were selected by a checkerboard assay. Antigen was diluted to 0, 01, 0.03, 0.1 and 0.3. mu.g/mL with coating buffer and antibody was diluted to 0.03, 0.1, 0.3 and 1. mu.g/mL with antibody diluent. After selection of the optimal working point, the serpentin standards were diluted to 8 concentrations (0, 0.27, 0.82, 2.47, 7.41, 22.22, 66.67, 200 ng/mL), followed by ic-ELISA protocol and finally mapped with originPro 8.5, as shown in FIG. 1. Obtaining DAS standard inhibition curve and calculating IC50。
Example 1: synthesis of serpentine hapten
The synthesis route is as follows:
the small serpentine molecule has no immunogenicity, and can not stimulate a mouse to generate immune response so as to generate an antibody, so that the serpentine needs to be coupled to protein by a protein connection technology to obtain the immunogenicity; active groups commonly used in the protein coupling technology comprise amino, carboxyl, hydroxyl, sulfydryl and the like, carboxyl is derived from DAS molecules, and a spacer arm is lengthened, so that small molecules can be fully exposed after being coupled with proteins, and the immune effect is improved.
1mg DAS was dissolved in 300. mu.L pyridine, then 7.2mg succinic anhydride and a catalytic amount of 3.4mg DMAP were added. The reaction is stirred for 5h at 50 ℃ in the dark. The reaction was then quenched by the addition of 50. mu.L of ultrapure water and blown dry with nitrogen. Extracting the residue with 1mL chloroform and 1mL water at a ratio of 1: 1 for three times, collecting organic substances, and sequentially drying with nitrogen to obtain derivative HS-DAS.
Example 2: synthesis of serpentine complete antigen
Dissolving the serpentine hapten (HA-DAS) in N, N-dimethylformamide solution, adding 3 times of serpentine substance amount of N-hydroxysuccinimide (NHS) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC), and reacting for 6-8h (called solution A) under magnetic stirring at room temperature. Adding 2000 times of S-streptocin hemocyanin (KLH) into phosphate buffer solution to obtain solution B (called solution B), dropwise adding the solution A into the solution B, reacting at room temperature overnight, dialyzing by PBS solution, and removing unreacted small molecule hapten to obtain complete antigen.
Example 3: synthesis of serpentine capsulgen
1mg DAS was dissolved in 200. mu. L N, N-dimethylformamide, 8mg N, N-Carbonyldiimidazole (CDI) was added and magnetic stirring was performed at 37 ℃ for 2 h. The reaction solution was added dropwise to 1mL of 0.05M sodium carbonate buffer (bovine serum albumin BSA 2 mg), stirred at room temperature overnight, dialyzed against 0.01M PBS for three days, and stored at-20 ℃. DAS-CDI-BSA acts as the coating antigen.
Example 4: preparation of hybridoma cell strain secreting serpentine rhzomorph monoclonal antibody
1. Obtaining immunity of animals
Mixing DAS complete antigen and equivalent Freund adjuvant, emulsifying, and performing neck and back subcutaneous multipoint injection immunization (except puncture immunization) on BALB/c mice; complete Freund adjuvant is used for the first immunization, and the dosage is 80. mu.g/vaccine; incomplete Freund's adjuvant is used for multiple times of boosting immunization, and the dosage is reduced by half to be 40 mu g/mouse; the thorny immunity does not use an adjuvant, the thorny immunity is directly diluted by normal saline and then injected into the abdominal cavity, and the dosage is reduced by half to obtain 20 mu g/mouse; one month is separated between the first immunization and the second boosting immunization, 21 days are separated between the multiple boosting immunizations, and 18-21 days are separated between the sprint immunization and the last boosting immunization; the immune effect of the mouse is observed by an indirect competitive enzyme-linked immunosorbent assay (ic-ELISA), namely the titer and inhibition of the mouse serum are detected;
2. cell fusion
After three days of the spurting immunization, cell fusion is carried out according to a conventional PEG (polyethylene glycol, molecular weight is 4000) method, and the specific steps are as follows:
a. taking eyeballs and blood, immediately putting the mice into 75% alcohol for disinfection after the mice are killed by a cervical vertebra dislocation method, soaking for about 5min, taking out the spleen of the mice by aseptic operation, properly grinding the spleen by using a rubber head of an injector, passing through a 200-mesh cell screen to obtain a spleen cell suspension, collecting, centrifuging (1200 rpm, 8 min), washing the spleen cells for three times by using an RPMI-1640 culture medium, diluting the spleen cells to a certain volume after the last centrifugation, and counting for later use;
b. collecting SP2/0 cells: 7-10 days before fusion, SP2/0 tumor cells were cultured in RPMI-1640 medium containing 10% FBS (fetal bovine serum) at 5% CO2In the incubator, SP2/0 tumor cell number is required to reach (1-4) x 10 before fusion7Ensuring SP2/0 tumor cells to be in logarithmic growth phase before fusion, collecting the tumor cells during fusion, suspending the tumor cells in RPMI-1640 basic culture solution, and counting the cells;
c. the fusion process is 7 min: 1min, 1mL of PEG 4000 was added to the cells dropwise from slow to fast; standing for 2 min; dropping 1mL of RPMI-1640 culture medium within 1min at 3min and 4 min; dropping 2mL of RPMI-1640 culture medium within 1min at 5min and 6 min; at 7min, 1mL of RPMI-1640 culture medium is added dropwise every 10 s; then carrying out warm bath at 37 ℃ for 5 min; centrifuging (800 rpm, 8 min), discarding supernatant, resuspending in RPMI-1640 screening medium containing 20% fetal calf serum, 2% 50 × HAT, adding to 96-well cell plate at 200 μ L/well, standing at 37 deg.C and 5% CO2Culturing in an incubator;
3. cell screening and cell line establishment
Performing RPMI-1640 screening culture medium half-exchange on fused cells on the 3 rd day of cell fusion, performing total-exchange with RPMI-1640 transitional culture medium containing 20% fetal calf serum and 1% 100 XHT on the 5 th day, and taking cell supernatant on the 7 th day for screening;
the screening is divided into two steps: firstly, screening out positive cell holes by using an ic-ELISA method, secondly, selecting serpentine as a standard substance, and determining the inhibition effect of positive cells by using the ic-ELISA method;
selecting a cell hole with good inhibition on a serpentine standard substance, carrying out subcloning by adopting a limiting dilution method, and carrying out detection by using the same method after seven days;
and carrying out subcloning for three times according to the method to finally obtain the serpentine monoclonal antibody cell strain.
Example 5: preparation and identification of serpentine monoclonal antibody
Taking BALB/c mice 8-10 weeks old, and injecting 1mL of sterile paraffin oil into the abdominal cavity of each mouse; 7 days later, each mouse was injected intraperitoneally with 1X 106Serpentine hybridoma cells, ascites fluid was collected from the seventh day, and antibody purification was performed on the ascites fluid by the octanoic acid-saturated ammonium sulfate method.
Under the condition of partial acid, the caprylic acid can precipitate other hybrid proteins except IgG immunoglobulin in the ascites, then the centrifugation is carried out, and the precipitate is discarded; then, the IgG type monoclonal antibody was precipitated with an ammonium sulfate solution of the same saturation, centrifuged, the supernatant was discarded, and the supernatant was dissolved in a 0.01M PBS solution (pH 7.4), dialyzed and desalted to finally obtain a purified monoclonal antibody, which was stored at-20 ℃.
Using an indirect competition ELISA, a graph was made using originPro 8.5, and the results are shown in FIG. 1. Obtaining a DAS standard inhibition curve, R thereof2 = 0.99946，Y = 0.207+1.631/[1+(x/5.967)1.039]The detection limit (the addition amount corresponding to the inhibition rate of 20-80%) is 1.57-22.6 ng/mL, IC50The value is 5.97ng/mL, the crossing rate of the analog of the serpentine is less than 1%, which indicates that the analog of the serpentine has good sensitivity to the serpentine and can be used for immunoassay detection of the serpentine.
(Cross-over Rate = (IC of Serpentine)50IC of/analogue50）×100%）
Example 6: application of serpentine rhzomorph monoclonal antibody
The monoclonal antibody prepared from the hybridoma cell strain through in-vivo ascites is applied to an ELISA addition recovery test of DAS, and the method comprises the following specific steps:
(1) coating a 96-well enzyme label plate with coating antigen with the concentration of 0.3 mu g/mL diluted by Carbonate Buffer Solution (CBS), coating 100 mu L of the enzyme label plate in each well at 37 ℃ for 2h, washing the plate with PBST washing liquor for three times, wherein 200 mu L of the washing liquor in each well is used for 3min, and drying by beating;
(2) sealing with CBS containing 0.2% gelatin, sealing at 37 deg.C for 2 hr with 200 μ L per well, washing the plate with PBST lotion for three times, each time with 200 μ L per well, each time for 3min, and drying;
(3) preparing 0, 0.27, 0.82, 2.47, 7.41, 22.22, 66.67 and 200 mu g/L of DAS standard solution by using Phosphate Buffered Saline (PBS), respectively adding the standard solution and the extract of a sample to be detected into a closed enzyme label plate, wherein each hole is 50 mu L, repeating 3 holes for each sample, adding 50 mu L of anti-DAS monoclonal antibody diluted by 1:32000 into each hole, reacting at 37 ℃ for 0.5h, and then washing and drying the plate;
(4) adding 100 μ L of HRP-labeled goat anti-mouse IgG secondary antibody diluted with PBS containing 0.1% gelatin at a ratio of 1:3000 into each well, reacting at 37 ℃ for 0.5h, washing and drying;
(5) adding 100 μ L of TMB developing solution into each well, developing at 37 deg.C for 15min, and adding 50 μ L of 2M H into each well2SO4Stopping solution, measuring the light absorption value at 450 nm;
(6) adding and recovering and sample pretreatment:
rice was selected as the test sample.
Washing and cutting the sample to be tested, weighing three samples (2 g each), and adding DAS standard (according to antibody linear range and IC) of 100ppb, 250ppb and 500ppb into the sample50Setting the adding concentration), adding 20mL of 25% ethanol-PBS extracting solution for extraction, violently shaking for 1h, centrifuging, and taking supernatant for dilution by 5 times. (i.e., a 50-fold dilution altogether to reduce the effect of the sample matrix).
The additive recovery test was performed by indirect competitive ELISA with 99%, 104%, and 110% recovery, respectively.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (8)
1. A hybridoma cell strain OVA15 secreting serpentine monoclonal antibody has been deposited in China general microbiological culture Collection center (CGMCC), China academy of sciences microorganism institute No. 3, West Lu No.1 institute of North Chen West Lu, Kyoho, Beijing, and is classified and named as monoclonal cell strain, the preservation date is 2019, 10 and 14 days, and the preservation number is CGMCC No. 18515.
2. A serpentine monoclonal antibody characterized by: it is secreted and produced by hybridoma cell strain OVA15 with the preservation number of CGMCC No.18515 as claimed in claim 1.
3. The use of a serpentine monoclonal antibody as claimed in claim 2, characterized in that: the method is used for detecting the serpentine bacterin residues in food.
4. The use of a serpentine monoclonal antibody according to claim 3, characterized in that: the food is specifically cereal.
5. The use of a serpentine monoclonal antibody according to claim 3, characterized in that: the detection method is to prepare a reagent for detecting the serpentin by an ELISA competition method.
6. The hybridoma cell line OVA15 according to claim 1, wherein: the preparation method of the serpentine complete antigen for preparing the hybridoma cell strain OVA15 comprises the following steps:
(1) preparation of serpentine hapten: reacting the serpentine with succinic anhydride to introduce active carboxyl to obtain serpentine hapten;
(2) preparation of a serpentin complete antigen: dissolving a serpentine hapten in an N, N-dimethylformamide solution, adding N-hydroxysuccinimide NHS and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC with 3 times of serpentine substance mass, and magnetically stirring at room temperature for 6-8h to obtain solution A; adding hemocyanin KLH with the mass of 2000 times of snakehead rhzomorph into a phosphate buffer solution to obtain a solution B; and dropwise adding the solution A into the solution B, reacting at room temperature overnight, dialyzing by using a PBS solution, and removing unreacted small molecule hapten to obtain the serpentine complete antigen.
7. The hybridoma cell line OVA15 according to claim 6, wherein the structural formula of the serpentine hapten is as follows:
8. the hybridoma cell line OVA15 according to claim 6, wherein the structural formula of the serpentine complete antigen is as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911272254.8A CN110724192B (en) | 2019-12-12 | 2019-12-12 | Hybridoma cell strain secreting serpentine monoclonal antibody and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911272254.8A CN110724192B (en) | 2019-12-12 | 2019-12-12 | Hybridoma cell strain secreting serpentine monoclonal antibody and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110724192A CN110724192A (en) | 2020-01-24 |
| CN110724192B true CN110724192B (en) | 2022-02-08 |
Family
ID=69225971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911272254.8A Active CN110724192B (en) | 2019-12-12 | 2019-12-12 | Hybridoma cell strain secreting serpentine monoclonal antibody and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110724192B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111896738B (en) * | 2020-08-03 | 2023-07-11 | 北京望尔生物技术有限公司 | Test strip for detecting serpentine bacterial element and application thereof |
| CN111896737B (en) * | 2020-08-03 | 2023-07-07 | 北京望尔生物技术有限公司 | Application of snake-shaped bacterial artificial antigen in enzyme-linked immunosorbent assay kit |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109280646A (en) * | 2018-10-30 | 2019-01-29 | 江南大学 | An anti-diclazuril-specific monoclonal antibody hybridoma cell line and its application |
-
2019
- 2019-12-12 CN CN201911272254.8A patent/CN110724192B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110724192A (en) | 2020-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104004717B (en) | The universal monoclonal antibody hybridoma cell strain of one strain aspergillus flavus resisting toxin and application thereof | |
| CN110607283A (en) | A hybridoma cell line CBC secreting dicofol monoclonal antibody and its application | |
| CN112877296A (en) | Anti-phenacetin monoclonal antibody hybridoma cell strain AD and preparation method and application thereof | |
| CN110724192B (en) | Hybridoma cell strain secreting serpentine monoclonal antibody and application thereof | |
| CN113637081A (en) | A hybridoma cell line secreting anti-pendimethalin monoclonal antibody and its application | |
| CN108251381B (en) | Paraquat monoclonal antibody hybridoma cell strain and application thereof | |
| CN107119022B (en) | Isobacteriumurea monoclonal antibody hybridoma cell strain ZXL-2 and application thereof | |
| CN104312978B (en) | A kind of TOB monoclonal antibody and preparation method and application | |
| CN112280745A (en) | Hybridoma cell strain capable of secreting pyridaben monoclonal antibody and application thereof | |
| CN110117575B (en) | A Hybridoma Cell Line HFG with Monoclonal Antibody to Pyrimmycamine and Its Application | |
| CN112458062B (en) | Ethyl maltol monoclonal antibody hybridoma cell strain and application thereof | |
| CN112574957A (en) | Hybridoma cell strain secreting clomazone monoclonal antibody and application thereof | |
| CN108948188B (en) | A hybridoma cell line J6 secreting clothianidin monoclonal antibody and its application | |
| CN110950962B (en) | A hybridoma cell line A11S secreting bisimibenzuron monoclonal antibody and its application | |
| CN113621583A (en) | A hybridoma cell line secreting dinoylmorpholine monoclonal antibody and its application | |
| CN112375744A (en) | Dihydropyridine monoclonal antibody hybridoma cell strain and application thereof | |
| CN105754954B (en) | An imidacloprid monoclonal antibody hybridoma cell line YH5 and its application | |
| CN116121199B (en) | Brucella monoclonal antibody 6A5 and its application and kit | |
| CN112501128A (en) | Forchlorfenuron monoclonal antibody hybridoma cell strain and application thereof | |
| CN111454912B (en) | A xylazine monoclonal antibody hybridoma cell line and its application | |
| CN105087500A (en) | Ribavirin monoclonal antibody hybridoma cell strain and application thereof | |
| CN113151188B (en) | Hybridoma cell strain capable of secreting diphenhydramine monoclonal antibody and application thereof | |
| CN110747173B (en) | Hybridoma cell strain HOT capable of secreting tricaine monoclonal antibody and application thereof | |
| US10696748B2 (en) | Hybridoma cell line of secreting clarithromycin monoclonal antibodies and preparation method thereof | |
| CN112813034A (en) | Hybridoma cell strain capable of secreting hymexazol monoclonal antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |